You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 142 No. 2, February 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on ISI (1)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Immunization
 •Dermatologic Disorders, Other
 •Drug Therapy
 •Adverse Effects
 •Public Health
 •Alert me on articles by topic

VIGNETTES
Vesicular Eczema After Intravenous Immunoglobulin Therapy for Treatment of Stevens-Johnson Syndrome

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Stevens-Johnson syndrome (SJS) is one of the most severe cutaneous eruptions occurring in children. The standard of care for treatment of patients with SJS is supportive. Off-label use of intravenous immunoglobulin (IVIG) has been used for treatment of many autoimmune and bullous diseases, including SJS,1 and is thought to have a relatively safe adverse effect profile. Serious adverse effects include anaphylaxis (in patients with IgA deficiency), renal tubular necrosis (in patients with renal insufficiency or dehydration), and aseptic meningitis. Minor adverse events occurring in approximately 10% of patients include headache, myalgia, chest discomfort, and fever.2 Adverse skin reactions occur rarely and include urticaria, pruritus, petechiae, alopecia, and leukocytoclastic vasculitis. In addition, vesicular eczema (a pompholyxlike eruption) has been reported in patients after therapy with IVIG for treatment of neurologic disease.3 We report a case of a pompholyxlike eruption occurring in a patient treated with IVIG for SJS. We hope to . . . [Full Text of this Article]

Report of a Case


Comment

AUTHOR INFORMATION
Priya K. Young, MD; Sun Young Ruggeri, MD; Sheila Galbraith, MD; Beth A. Drolet, MD


RELATED ARTICLE

Severe Eczematous Skin Reaction After High-Dose Intravenous Immunoglobulin Infusion: Report of 4 Cases and Review of the Literature
Gianluca Vecchietti, Katrin Kerl, Christa Prins, Gürkan Kaya, Jean-Hilaire Saurat, and Lars E. French
Arch Dermatol. 2006;142(2):213-217.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.